CLAIMS

1. Use of a TACI-Fc fusion protein in the manufacture of a medicament for treating IgA nephropathy, wherein the TACI-Fc fusion protein comprises:

(i) a TACI extracellular region or a fragment thereof binding to Blys and/or APRIL; and

(ii) a human immunoglobulin constant region.

2. The use according to claim 1, wherein the TACI extracellular region or the fragment thereof binding to Blys and/or APRIL comprises an amino acid sequence set forth in SEQ ID NO: 1.

3. The use according to claim 2, wherein the human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, or at least 96% identity to SEQ ID NO: 2.

4. The use according to claim 3, wherein the human immunoglobulin constant region comprises one or more modifications of amino acid at positions 3, 8, 14, 15, 17, 110, 111 or 173 of SEQ ID NO: 2.

5. The use according to claim 4, wherein the modification is substitution, deletion or insertion of amino acid.

6. The use according to claim 5, wherein the substitution is selected from the group consisting of P3T, L8P, L14A, L15E, G17A, A110S, P111S and A173T.

7. The use according to claim 6, wherein the human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 3.

8. The use according to claim 7, wherein the human immunoglobulin is IgG1.

9. The use according to claim 8, wherein the TACI-Fc fusion protein comprises an amino acid sequence set forth in SEQ ID NO: 4.

10. The use according to claim 9, wherein the TACI-Fc fusion protein is Telitacicept.

11. The use according to any one of claims 1-10, wherein the TACI-Fc fusion protein is administered at a dose ranging from 160 to 240 mg each time, more preferably 160 mg or 240 mg each time.

12. The use according to any one of claims 1-10, wherein the TACI-Fc fusion protein is administered 2-4 times per month and/or administered continuously for about 2-50 weeks.

13. The use according to any one of claims 1-10, wherein the TACI-Fc fusion protein is administered by subcutaneous injection, intramuscular injection, oral or intravenous administration.

14. The use according to claim 1, wherein the IgA nephropathy is primary IgA nephropathy.

15. The use according to claim 1, wherein the TACI-Fc fusion protein is in a pharmaceutical composition, and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.